EP1019091A4 - 50 proteines secretees d'origine humaine - Google Patents

50 proteines secretees d'origine humaine

Info

Publication number
EP1019091A4
EP1019091A4 EP98943536A EP98943536A EP1019091A4 EP 1019091 A4 EP1019091 A4 EP 1019091A4 EP 98943536 A EP98943536 A EP 98943536A EP 98943536 A EP98943536 A EP 98943536A EP 1019091 A4 EP1019091 A4 EP 1019091A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98943536A
Other languages
German (de)
English (en)
Other versions
EP1019091A1 (fr
Inventor
Paul A Moore
Steven M Ruben
David W Lafleur
Yang-Gu Shi
Graig A Rosen
Henrik S Olsen
Reinhard Ebner
Laurie A Brewer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1019091A1 publication Critical patent/EP1019091A1/fr
Publication of EP1019091A4 publication Critical patent/EP1019091A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
EP98943536A 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine Withdrawn EP1019091A4 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US5766397P 1997-09-05 1997-09-05
US5766997P 1997-09-05 1997-09-05
US5762697P 1997-09-05 1997-09-05
US57669P 1997-09-05
US57626P 1997-09-05
US57663P 1997-09-05
US5866697P 1997-09-12 1997-09-12
US5897397P 1997-09-12 1997-09-12
US5897497P 1997-09-12 1997-09-12
US5866797P 1997-09-12 1997-09-12
US58973P 1997-09-12
US58974P 1997-09-12
US58667P 1997-09-12
PCT/US1998/018360 WO1999011293A1 (fr) 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine
US58666P 2008-06-04

Publications (2)

Publication Number Publication Date
EP1019091A1 EP1019091A1 (fr) 2000-07-19
EP1019091A4 true EP1019091A4 (fr) 2005-05-11

Family

ID=27568129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98943536A Withdrawn EP1019091A4 (fr) 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine

Country Status (5)

Country Link
EP (1) EP1019091A4 (fr)
JP (2) JP2001514024A (fr)
AU (1) AU9130498A (fr)
CA (1) CA2302808C (fr)
WO (1) WO1999011293A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002591A1 (en) 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999055868A2 (fr) * 1998-04-24 1999-11-04 Genentech, Inc. Proteines fizz
US6503730B1 (en) 1997-06-19 2003-01-07 Schering Corporation Nucleic acids encoding a cysteine rich protein
ATE525390T1 (de) * 1999-04-27 2011-10-15 Univ Pennsylvania Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
EP1255831A2 (fr) 2000-01-19 2002-11-13 The University Of Virginia Patent Foundation Proteines specifiques du sperme
WO2001060859A1 (fr) * 2000-02-21 2001-08-23 Kureha Chemical Industry Co., Ltd. Nouvelles proteines et nouveaux genes codant ces proteines
EP1138765A1 (fr) * 2000-03-27 2001-10-04 Leadd B.V. Protéines AAP-5 et AAP-6 associées à l'apoptine
EP1138768A3 (fr) * 2000-03-27 2002-08-07 Leadd B.V. Protéine AAP-5 liant l' apoptine
ES2296829T3 (es) * 2000-11-06 2008-05-01 Cancer Research Technology Limited Imaginologia, diagnostico y tratamiento de la enfermedad.
WO2002057420A2 (fr) * 2001-01-18 2002-07-25 Human Genome Sciences, Inc. 50 proteines secretees humaines
EP1399460A4 (fr) * 2001-04-27 2005-04-13 Sunnybrook & Women S College H Genes associes au cancer du sein et utilisations correspondantes
US7109302B1 (en) 2002-04-01 2006-09-19 Human Genome Sciences, Inc. Antibodies that specifically bind to GMAD
ATE462727T1 (de) 2002-11-20 2010-04-15 Cancer Rec Tech Ltd An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
US20110038885A1 (en) * 2007-07-26 2011-02-17 Zheng Xin Dong Chemokine analogs
MX393006B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
KR20190137936A (ko) 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
CA3067455C (fr) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent de prevention ou de traitement de l'ataxie spinocerebelleuse
JP7227914B2 (ja) * 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386931A1 (fr) * 1998-03-25 2004-02-04 Genentech, Inc. Homologue humain du neurotrimin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386931A1 (fr) * 1998-03-25 2004-02-04 Genentech, Inc. Homologue humain du neurotrimin

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADAMS M E ET AL: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence", NATURE (LONDON), vol. 377, no. 6547 SUPPL., 1995, pages 3 - 174, XP002916734, ISSN: 0028-0836 *
DATABASE OMIM XP002318683, retrieved from OMIM accession no. 605158 *
GUBLER AND HOFFMAN: "A SIMPLE AND VERY EFFICIENT METHOD FOR GENERATING cDNA LIBRARIES", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 25, 1983, pages 263 - 269, XP002144172, ISSN: 0378-1119 *
HEIJNE VON G: "A NEW METHOD FOR PREDICTING SIGNAL SEQUENCE CLEAVAGE SITES", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 11, 1986, pages 4683 - 4690, XP001189533, ISSN: 0305-1048 *
KIDD T ET AL: "Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 92, 23 January 1998 (1998-01-23), pages 205 - 215, XP002094383, ISSN: 0092-8674 *
NIELSEN H ET AL: "IDENTIFICATION OF PROKARYOTIC AND EUKARYOTIC SIGNAL PEPTIDES AND PREDICTION OF THEIR CLEAVAGE SITES", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 1, 1997, pages 1 - 6, XP002072638, ISSN: 0269-2139 *
See also references of WO9911293A1 *
ZHANG W-R ET AL: "MOLECULAR CLONING AND EXPRESSION OF A UNIQUE RECEPTOR-LIKE PROTEIN-TYROSINE-PHOSPHATASE IN THE LEUCOCYTE-COMMON-ANTIGEN-RELATED PHOSPHATASE FAMILY", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 302, no. PART 1, 15 August 1994 (1994-08-15), pages 39 - 47, XP009024545, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
CA2302808A1 (fr) 1999-03-11
AU9130498A (en) 1999-03-22
CA2302808C (fr) 2010-05-18
JP2001514024A (ja) 2001-09-11
EP1019091A1 (fr) 2000-07-19
WO1999011293A1 (fr) 1999-03-11
JP2009131263A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
EP1100869A4 (fr) 98 proteines humaines secretees
EP1039801A4 (fr) 207 proteines humaines secretees
EP1088071A4 (fr) 94 proteines humaines secretees
EP1000084A4 (fr) 123 proteines humaines secretees
EP1040117A4 (fr) 110 proteines secretees humaines
EP1109821A4 (fr) 49 proteines humaines secretees
AU6552198A (en) 28 human secreted proteins
EP1019091A4 (fr) 50 proteines secretees d'origine humaine
EP1140970A4 (fr) 47 proteines humaines secretees
AU6952998A (en) 20 human secreted proteins
EP1051426A4 (fr) 67 proteines humaines secretees
EP1064297A4 (fr) 95 proteines humaines secretees
EP1044211A4 (fr) 36 proteines humaines secretees
EP1005544A4 (fr) 70 proteines secretees humaines
AU8066998A (en) 86 human secreted proteins
EP1097199A4 (fr) 71 proteines humaines secretees
EP1124850A4 (fr) 12 proteines humaines secretees
EP1032838A4 (fr) 125 proteines secretees humaines
EP1062236A4 (fr) 31 proteines humaines secretees
AU8404598A (en) 64 human secreted proteins
EP1009766A4 (fr) 19 proteines secretees humaines
EP1159284A4 (fr) 33 proteines humaines secretees
EP1002132A4 (fr) 90 proteines secretees humaines
EP1042674A4 (fr) 148 proteines humaines secretees
EP1018551A4 (fr) Proteine megsine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20050322

17Q First examination report despatched

Effective date: 20050602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060905